Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142342 | 0.90 | ALDH1A1 (0.42) | ALDH1A1LMNACSNK1DKDM4ENPSR1 | |
| SCHEMBL7141518 | 0.90 | ITGB3 (0.47) | ALDH1A1ITGB3ITGA2BMEN1KMT2A | |
| SCHEMBL7138145 | 0.88 | MAPT (0.41) | ALDH1A1LMNACSNK1DKDM4ENPSR1 | |
| Hydrochloric Acid SCHEMBL8067753 | 0.84 | ALDH1A1 (0.56) | ALDH1A1LMNACSNK1DKDM4ENPSR1 | |
| SCHEMBL7141536 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1LMNAKDM4EITGB3ITGA2B | |
| SCHEMBL7141143 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNAKDM4ERAB9AMEN1 | |
| SCHEMBL7136545 | 0.80 | ITGB3 (0.49) | ALDH1A1LMNAITGB3ITGA2BMEN1 | |
| SCHEMBL7143985 | 0.77 | ALDH1A1 (0.51) | ALDH1A1LMNACSNK1DKDM4ENPSR1 | |
| SCHEMBL7140086 | 0.77 | MEN1 (0.46) | ALDH1A1LMNACSNK1DKDM4ENPSR1 | |
| SCHEMBL7143526 | 0.76 | ITGB3 (0.47) | ITGB3ITGA2BMEN1KMT2ASLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | claimed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| EP-0886649-A4 | PROTEIN OCCLUSION FOR DELIVERY OF SMALL MOLECULES | PANAYOTATOS NIKOS (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| EP-0886649-A1 | PROTEIN OCCLUSION FOR DELIVERY OF SMALL MOLECULES | Panayotatos, Nikos (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0882022-A1 | ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0866696-A1 | TREATMENT OF THE CNS EFFECTS OF HIV WITH VX-478, ALONE OR IN COMBINATION WITH AZT OR 3TC | Vertex Pharmaceuticals Incorporated (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997040028-A1 | UREA DERIVATIVES AS INHIBITORS OF IMPDH ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997026275-A1 | PROTEIN OCCLUSION FOR DELIVERY OF SMALL MOLECULES | PANAYOTATOS NIKOS (US) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997020554-A1 | TREATMENT OF THE CNS EFFECTS OF HIV WITH VX-478, ALONE OR IN COMBINATION WITH AZT OR 3TC | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | ALDH1A1 1400/4885LMNA 3184/4885CSNK1D 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.